Mr. Crawford will be responsible for establishing and managing Clearside’s global supply chain for clinical testing, training and, if approved, trade distribution of suprachoroidal CLS-TA, the company’s proprietary suspension of the corticosteroid triamcinolone acetonide formulated for administration to the back of the eye via the suprachoroidal space.
In a career spanning more than 25 years, Mr. Crawford has extensive expertise in supply chain management, trade relations, product launches, and manufacturing operations. Before joining Clearside, he was Vice President of Supply Chain and Customer Service for
“Thomas brings an important depth of manufacturing operations and supply chain management experience to the company,” said Clearside’s Chief Executive Officer and President,
Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe”, “expect”, “may”, “plan”, “potential”, “will”, and similar expressions, and are based on Clearside’s current beliefs and expectations. These forward-looking statements include expectations regarding the clinical development of Clearside’s product candidates, and the timing of a potential submission of an NDA with the